{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:04:42Z","timestamp":1788498282942,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:00:00Z","timestamp":1722038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["ZIA BC 011054"],"award-info":[{"award-number":["ZIA BC 011054"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000051","name":"National Human Genome Research Institute","doi-asserted-by":"publisher","award":["ZIA HG200323"],"award-info":[{"award-number":["ZIA HG200323"]}],"id":[{"id":"10.13039\/100000051","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.canlet.2024.217129","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T11:41:05Z","timestamp":1721648465000},"page":"217129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer"],"prefix":"10.1016","volume":"608","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-6255","authenticated-orcid":false,"given":"Sushil Kumar","family":"Jaiswal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2327-420X","authenticated-orcid":false,"given":"Kevin","family":"Fedkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4687-2456","authenticated-orcid":false,"given":"Ronak","family":"Khamar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4090-113X","authenticated-orcid":false,"given":"Hua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7857-3309","authenticated-orcid":false,"given":"Valer","family":"Gotea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3633-2299","authenticated-orcid":false,"given":"Sonam","family":"Raj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2715-2904","authenticated-orcid":false,"given":"Michael","family":"Fedkenheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdel","family":"Elkahloun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1245-1338","authenticated-orcid":false,"given":"Lisa M.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina M.","family":"Annunziata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1065-019X","authenticated-orcid":false,"given":"Laura","family":"Elnitski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2024.217129_bib1","unstructured":"Society, A.C. Ovarian cancer risk factors. [cited 2022 April 29]; Available from: https:\/\/www.cancer.org\/cancer\/ovarian-cancer\/causes-risks-prevention\/risk-factors.html."},{"issue":"1","key":"10.1016\/j.canlet.2024.217129_bib2","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canlet.2024.217129_bib3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/OTT.S363856","article-title":"An effective hormonal therapy for a patient with Estrogen Receptor 1 (ESR1)-amplified metastatic ovarian cancer: a case report","volume":"15","author":"Wang","year":"2022","journal-title":"OncoTargets Ther."},{"issue":"9","key":"10.1016\/j.canlet.2024.217129_bib4","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1470-2045(13)70253-5","article-title":"Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study","volume":"14","author":"Sieh","year":"2013","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217129_bib5","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ygyno.2017.06.036","article-title":"Clinical benefit and risk of death with endocrine therapy in ovarian cancer: a comprehensive review and meta-analysis","volume":"146","author":"Paleari","year":"2017","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.canlet.2024.217129_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061647","article-title":"Estrogen signaling and its potential as a target for therapy in ovarian cancer","volume":"12","author":"Langdon","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.canlet.2024.217129_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030759","article-title":"Hormonal therapy for gynecological cancers: how far has science progressed toward clinical applications?","volume":"14","author":"Mitra","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.canlet.2024.217129_bib8","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/bjc.1994.281","article-title":"Effects of 4-hydroxytamoxifen and a novel pure antioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro","volume":"70","author":"DeFriend","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2024.217129_bib9","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.2147\/DDDT.S380925","article-title":"Oral selective estrogen receptor degraders (SERDs) in breast cancer: advances, challenges, and current status","volume":"16","author":"Downton","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.canlet.2024.217129_bib10","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.canlet.2024.217129_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fonc.2013.00296","article-title":"Current status and evolution of preclinical drug development models of epithelial ovarian cancer","volume":"3","author":"Konstantinopoulos","year":"2013","journal-title":"Front. Oncol."},{"issue":"Suppl 6","key":"10.1016\/j.canlet.2024.217129_bib12","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.canlet.2024.217129_bib13","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ygyno.2009.01.012","article-title":"A phase II study of Fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer","volume":"113","author":"Argenta","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2024.217129_bib14","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ygyno.2020.09.049","article-title":"Endocrine therapy in the management of low-grade serous ovarian\/peritoneal carcinoma: mounting evidence for therelative efficacy of tamoxifen and aromatase inhibitors","volume":"159","author":"Gershenson","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"15","key":"10.1016\/j.canlet.2024.217129_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14153790","article-title":"Detection of ESR1 mutations in primary tumors and plasma cell-free dna in high-grade serous ovarian carcinoma patients","volume":"14","author":"Stergiopoulou","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.canlet.2024.217129_bib16","doi-asserted-by":"crossref","DOI":"10.3892\/or.2021.8174","article-title":"Hormone therapy for ovarian cancer: emphasis on mechanisms and applications","volume":"46","author":"Li","year":"2021","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.canlet.2024.217129_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13046-021-01974-y","article-title":"Super-enhancers: a new frontier for epigenetic modifiers in cancer chemoresistance","volume":"40","author":"Li","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.canlet.2024.217129_bib18","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1158\/0008-5472.CAN-19-0215","article-title":"Chemotherapy-induced distal enhancers drive transcriptional programs to maintain the chemoresistant state in ovarian cancer","volume":"79","author":"Shang","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2024.217129_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12920-019-0520-9","article-title":"Integrated high-throughput analysis identifies super enhancers associated with chemoresistance in SCLC","volume":"12","author":"Bao","year":"2019","journal-title":"BMC Med. Genom."},{"issue":"3","key":"10.1016\/j.canlet.2024.217129_bib20","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.cell.2019.03.010","article-title":"A multiscale map of the stem cell state in pancreatic adenocarcinoma","volume":"177","author":"Lytle","year":"2019","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.canlet.2024.217129_bib21","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.cell.2014.08.027","article-title":"Enhancer activation requires trans-recruitment of a mega transcription factor complex","volume":"159","author":"Liu","year":"2014","journal-title":"Cell"},{"issue":"6400","key":"10.1016\/j.canlet.2024.217129_bib22","doi-asserted-by":"crossref","DOI":"10.1126\/science.aar3958","article-title":"Coactivator condensation at super-enhancers links phase separation and gene control","volume":"361","author":"Sabari","year":"2018","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.canlet.2024.217129_bib23","first-page":"7182","article-title":"Hippo-YAP signaling controls lineage differentiation of mouse embryonic stem cells through modulating the formation of super-enhancers","volume":"48","author":"Sun","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"7","key":"10.1016\/j.canlet.2024.217129_bib24","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cell.2018.10.042","article-title":"Transcription factors activate genes through the phase-separation capacity of their activation domains","volume":"175","author":"Boija","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2024.217129_bib25","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1186\/s12885-021-08276-8","article-title":"Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer","volume":"21","author":"Li","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2024.217129_bib26","first-page":"247","article-title":"Flow cytometric DNA analysis of human cancer cell lines","volume":"88","author":"Mullen","year":"2004","journal-title":"Methods Mol. Med."},{"issue":"8","key":"10.1016\/j.canlet.2024.217129_bib27","article-title":"Measuring survival of adherent cells with the colony-forming assay","volume":"2016","author":"Crowley","year":"2016","journal-title":"Cold Spring Harb. Protoc."},{"issue":"6","key":"10.1016\/j.canlet.2024.217129_bib28","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst"},{"issue":"W1","key":"10.1016\/j.canlet.2024.217129_bib29","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"8","key":"10.1016\/j.canlet.2024.217129_bib30","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1172\/JCI21739","article-title":"Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer","volume":"117","author":"Chu","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"6497","key":"10.1016\/j.canlet.2024.217129_bib31","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1126\/science.aaz4427","article-title":"Partitioning of cancer therapeutics in nuclear condensates","volume":"368","author":"Klein","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.canlet.2024.217129_bib32","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41594-019-0190-5","article-title":"Phase separation of ligand-activated enhancers licenses cooperative chromosomal enhancer assembly","volume":"26","author":"Nair","year":"2019","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"14","key":"10.1016\/j.canlet.2024.217129_bib33","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1074\/jbc.M510809200","article-title":"Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha","volume":"281","author":"Long","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"7327","key":"10.1016\/j.canlet.2024.217129_bib34","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature09504","article-title":"Selective inhibition of BET bromodomains","volume":"468","author":"Filippakopoulos","year":"2010","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.canlet.2024.217129_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.151851","article-title":"Targeting ESR1 mutation-induced transcriptional addiction in breast cancer with BET inhibition","volume":"7","author":"Udden","year":"2022","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.canlet.2024.217129_bib36","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/rmb2.12006","article-title":"Molecular mechanism of estrogen-estrogen receptor signaling","volume":"16","author":"Yasar","year":"2017","journal-title":"Reprod. Med. Biol."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352400524X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030438352400524X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:54:46Z","timestamp":1778684086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030438352400524X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":36,"alternative-id":["S030438352400524X"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217129","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Megacomplex protects ER-alpha from degradation by Fulvestrant in epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2024.217129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217129"}}